Quantcast

Latest Paliperidone Stories

2014-05-13 08:33:18

New submission based on positive data from a 15-month schizoaffective relapse prevention study TITUSVILLE, N.J., May 13, 2014 /PRNewswire/ -- Janssen Pharmaceuticals, Inc., today announced the submission of supplemental New Drug Applications (sNDAs) for once-monthly atypical long-acting antipsychotic INVEGA(®) SUSTENNA(®) (paliperidone palmitate) to the U.S. Food and Drug Administration (FDA) for approval to treat schizoaffective disorder as either monotherapy or adjunctive...

2014-05-07 23:14:54

Flood Law Group announced today that it is now available to investigate claims related to complications from taking prescription Invega extended release tablets. Invega, also known by its generic name paliperidone, may contribute to an increased risk of leukopenia and neutropenia and gynecomastica according to the FDA. Washington, D.C. (PRWEB) May 07, 2014 Flood Law Group released a statement today announcing that it is now available to investigate potential claims on behalf of people who...

2014-05-06 16:32:22

Demonstrated significant efficacy in manic and depressive mood symptoms and psychosis, and improved patient functioning TITUSVILLE, N.J., May 6, 2014 /PRNewswire/ -- Janssen Pharmaceuticals, Inc., today announced the results of the company's schizoaffective relapse prevention study of once-monthly atypical long-acting antipsychotic INVEGA(®) SUSTENNA(® )(paliperidone palmitate). The trial found INVEGA(®) SUSTENNA(®) met its primary endpoint of delayed time to and reduced risk of...

2014-05-05 08:29:33

First prospective, randomized clinical trial to reflect context of "real world" issues in treating schizophrenia, including recent incarceration and substance abuse TITUSVILLE, N.J., May 5, 2014 /PRNewswire/ -- Janssen Pharmaceuticals, Inc., today announced the results of its landmark PRIDE (Paliperidone Palmitate Research In Demonstrating Effectiveness) trial. PRIDE is the first prospective, randomized clinical trial to compare schizophrenia medications within the context of many...

2014-04-22 08:34:04

TITUSVILLE, N.J., April 22, 2014 /PRNewswire/ -- Janssen Pharmaceuticals, Inc., and Janssen Research and Development, LLC, both members of the Johnson & Johnson Family of Companies, announced that several posters related to the company's work in mental health will be featured at the 167(th) Annual Meeting of the American Psychiatric Association (APA) in New York City May 3 to 7. The posters are: -- Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE):...

2014-04-06 23:01:17

Study Released as Risperdal Lawsuits Alleging Use of Antipsychotic Drug Caused Gynecomastia (Male Breast Growth) in Men and Boys Continue to Move Forward in Pennsylvania Columbus, OH (PRWEB) April 06, 2014 Wright & Schulte LLC, an experienced law firm representing clients in Risperdal lawsuits, notes that a new study has linked use of the atypical antipsychotic medication to gynecomastia, or male breast growth. The release of the study, which was presented in March at the 2014 Annual...

2014-04-02 23:01:07

The Firm continues to investigate Risperdal lawsuits that allege the atypical antipsychotic drug caused male breast development, or gynecomastia. New York, New York (PRWEB) April 02, 2014 The nationwide law firm of Bernstein Liebhard LLP is actively filing Risperdal lawsuits (http://www.risperdallawsuitcenter.com/) on behalf of individuals who allegedly suffered gynecomastia, or male breast growth, due to their use of the atypical antipsychotic. On March 26, 2014, the Firm filed a claim...

2014-03-20 08:29:49

Independent Data Monitoring Committee Recommends Halting Trial and Unblinding Data Based on Treatment Efficacy TITUSVILLE, N.J., March 20, 2014 /PRNewswire/ -- Janssen Research & Development, LLC announced today that following an Independent Data Monitoring Committee (IDMC) recommendation based on positive efficacy, it has halted early a Phase 3 clinical study of paliperidone palmitate 3-month formulation, an investigational treatment for symptoms of schizophrenia in adults. "We are...

2014-02-11 08:25:00

DUBLIN, Feb. 11, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/5nldqw/sustained_release ) has announced the addition of the "Sustained Release Injectables to 2020" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Formulations, Dosing, Devices, Markets and Forecasts The ability to formulate injectable drugs to increase the duration of efficacy for a given dose and simultaneously reduce the dosing frequency...

2013-11-05 23:26:47

The Agreement Settles Charges that Johnson & Johnson Illegally Marketed Risperdal, Invega and Natracor for Off-Label Use and Paid Kick-Backs to Physicians to Drive Sales of Risperdal and Invega, Alonso Krangle LLP reports. New York, NY (PRWEB) November 05, 2013 Johnson & Johnson has agreed to pay $2.2 billion to settle charges with the U.S. Department of Justice (DOJ) over the alleged illegal marketing of Risperdal, Invega and Natrecor, Alonso Krangle LLP reports. In a press...


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related